keyword
MENU ▼
Read by QxMD icon Read
search

Tumor lysis

keyword
https://www.readbyqxmd.com/read/29909407/familial-forms-of-cushing-syndrome-in-primary-pigmented-nodular-adrenocortical-disease-presenting-with-short-stature-and-insidious-symptoms-a-clinical-series
#1
Constanza Navarro Moreno, Amaury Delestienne, Etienne Marbaix, Selda Aydin, Konstanze Hörtnagel, Sarah Lechner, Yves Sznajer, Véronique Beauloye, Dominique Maiter, Philippe A Lysy
Cushing syndrome (CS) is a rare disease in children, frequently associated with subtle or periodic symptoms that may delay its diagnosis. Weight gain and growth failure, the hallmarks of hypercortisolism in pediatrics, may be inconsistent, especially in ACTH-independent forms of CS. Primary pigmented nodular adrenocortical disease (PPNAD) is the rarest form of ACTH-independent CS, and can be associated with endocrine and nonendocrine tumors, forming the Carney complex (CNC). Recently, phenotype/genotype correlations have been described with particular forms of CNC where PPNAD is isolated or associated only with skin lesions...
June 15, 2018: Hormone Research in Pædiatrics
https://www.readbyqxmd.com/read/29905398/comparison-of-fixed-versus-traditional-weight-based-dosing-of-rasburicase-in-a-pediatric-population
#2
Dimitrios A Savva, Nicole Herrera, Radha Rohatgi
BACKGROUND: The American Society of Clinical Oncology guidelines recommend rasburicase for the treatment of pediatric patients with hyperuricemia at risk of tumor lysis syndrome (TLS) using a weight-based dose of 0.1-0.2 mg/kg once daily for 1-7 days. However, there has been a trend in practice due to recent data showing benefit using a fixed-dose approach. The purpose of this study was to evaluate the efficacy and safety between fixed and weight-based dosing of rasburicase in a pediatric population...
June 15, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29900037/nanocomplex-based-tp53-gene-therapy-promotes-anti-tumor-immunity-through-tp53-and-sting-dependent-mechanisms
#3
Ellen C Moore, Lillian Sun, Paul E Clavijo, Jay Friedman, Joe B Harford, Anthony D Saleh, Carter Van Waes, Esther H Chang, Clint T Allen
Loss or mutation of TP53 has been linked to alterations in anti-tumor immunity as well as dysregulation of cell cycle and apoptosis. We explored immunologic effects and mechanisms following restoration of wild-type human TP53 cDNA in murine oral cancer cells using the therapeutic nanocomplex scL-53. We demonstrated scL-53 induces dose-dependent expression of TP53 and induction of apoptosis and immunogenic cell death. We further demonstrated both TP53-dependent and independent induction of tumor cell immunogenicity through the use of blocking mAbs, nanocomplex loaded with DNA plasmid with or without TP53 cDNA, empty nanocomplex and siRNA knockdown techniques...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29900010/hypoxia-restrains-the-expression-of-complement-component-9-in-tumor-associated-macrophages-promoting-non-small-cell-lung-cancer-progression
#4
Lei Li, Hong Yang, Yan Li, Xiao-Dong Li, Ting-Ting Zeng, Su-Xia Lin, Ying-Hui Zhu, Xin-Yuan Guan
The tumor microenvironment, including stroma cells, signaling molecules, and the extracellular matrix, critically regulates the growth and survival of cancer cells. Dissecting the active molecules in tumor microenvironment may uncover the key factors that can impact cancer progression. Human NSCLC tumor tissue-conditioned medium (TCM) and adjacent nontumor tissue-conditioned medium (NCM) were used to treat two NSCLC cells LSC1 and LAC1, respectively. Cell growth and foci formation assays were applied to assess the effects of TCM and NCM on cancer cells...
2018: Cell Death Discovery
https://www.readbyqxmd.com/read/29891487/anti-psma-cd3-bispecific-antibody-delivery-and-anti-tumor-activity-using-a-polymeric-depot-formulation
#5
Wilhem Leconet, He Liu, Ming Guo, Sophie Le Lamer-Déchamps, Charlotte Molinier, Sae Kim, Tjasa Vrlinic, Murielle Oster, Fang Liu, Vincent Navarro, Jaspreet S Batra, Adolfo Lopez-Noriega, Sylvestre Grizot, Neil H Bander
Small therapeutic proteins represent a promising novel approach to treat cancer. Nevertheless, their clinical application is often adversely impacted by their short plasma half-life. Controlled long-term delivery of small biologicals has become a challenge because of their hydrophilic properties and in some cases their limited stability. Here, an in-situ forming depot injectable polymeric system was used to deliver BiJ591, a Bispecific T-cell Engager (BiTE) targeting both prostate-specific membrane antigen (PSMA) and the CD3 T-cell receptor in prostate cancer...
June 11, 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29880613/real-world-outcomes-and-management-strategies-for-venetoclax-treated-chronic-lymphocytic-leukemia-patients-in-the-united-states
#6
Anthony R Mato, Meghan Thompson, John N Allan, Danielle M Brander, John M Pagel, Chaitra S Ujjani, Brian T Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P Skarbnik, Jeffrey J Pu, Paul M Barr, Alison R Sehgal, Bruce D Cheson, Clive S Zent, Hande H Tuncer, Stephen J Schuster, Peter V Pickens, Nirav N Shah, Andre Goy, Allison M Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M Gashonia, Arun K Singavi, Lindsey E Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R Furman, Chadi Nabhan
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with CLL treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated IGHV, 45% del(17p), and 26...
June 7, 2018: Haematologica
https://www.readbyqxmd.com/read/29873383/sequencing-of-human-genomes-extracted-from-single-cancer-cells-isolated-in-a-valveless-microfluidic-device
#7
Rodolphe Marie, Marie Pødenphant, Kamila Koprowska, Loic Bærlocher, Roland C M Vulders, Jennifer Wilding, Neil Ashley, Simon J McGowan, Dianne van Strijp, Freek van Hemert, Tom Olesen, Niels Agersnap, Brian Bilenberg, Celine Sabatel, Julien Schira, Anders Kristensen, Walter Bodmer, Pieter J van der Zaag, Kalim U Mir
Sequencing the genomes of individual cells enables the direct determination of genetic heterogeneity amongst cells within a population. We have developed an injection-moulded valveless microfluidic device in which single cells from colorectal cancer derived cell lines (LS174T, LS180 and RKO) and fresh colorectal tumors have been individually trapped, their genomes extracted and prepared for sequencing using multiple displacement amplification (MDA). Ninety nine percent of the DNA sequences obtained mapped to a reference human genome, indicating that there was effectively no contamination of these samples from non-human sources...
June 6, 2018: Lab on a Chip
https://www.readbyqxmd.com/read/29866746/development-of-mgd007-a-gpa33-x-cd3-bispecific-dart%C3%A2-protein-for-t-cell-immunotherapy-of-metastatic-colorectal-cancer
#8
Paul A Moore, Kalpana Shah, Yinhua Yang, Ralph Alderson, Penny Roberts, Vatana Long, Daorong Liu, Jonathan C Li, Steve Burke, Valentina Ciccarone, Hua Li, Claudia B Fieger, Jeff Hooley, Ann Easton, Monica Licea, Sergey Gorlatov, Kathleen L King, Peter Young, Arash Adami, Deryk Loo, Gurunadh R Chichili, Liqin Liu, Douglas H Smith, Jennifer G Brown, Francine Z Chen, Scott Koenig, Jennie Mather, Ezio Bonvini, Syd Johnson
We have developed MGD007 (anti-glycoprotein A33 x anti-CD3), a DART® protein designed to redirect T-cells to target gpA33 expressing colon cancer. The gpA33 target was selected based on an antibody-based screen to identify cancer antigens universally expressed in both primary and metastatic CRC specimens, including putative cancer stem cell populations. MGD007 displays the anticipated bispecific binding properties and mediates potent lysis of gpA33-positive cancer cell lines, including models of colorectal cancer stem cells, through recruitment of T-cells...
June 4, 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29850628/tag7-pglyrp1-can-induce-an-emergence-of-the-cd3-cd4-cd25-cd127-cells-with-antitumor-activity
#9
T N Sharapova, E A Romanova, L P Sashchenko, D V Yashin
We have shown that in the human peripheral blood cells, the innate immunity protein Tag7 can activate a subpopulation of CD3+CD4+CD25+ cells, which have antitumor activity. These cells can induce lysis of HLA-negative tumor cell lines. The Hsp70 stress molecule on the surface of the tumor cells is used as a recognition target, while the Tag7 protein on the lymphocyte membrane acts as a receptor for Hsp70. We have also demonstrated that this subpopulation of the CD4+CD25+ cells is CD127 positive and hence is not the Treg cells...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29845102/tumor-lysis-syndrome-associated-with-docetaxel-and-carboplatin-in-a-case-with-recurrent-endometrial-cancer
#10
Tomomichi Ito, Tsuyoshi Ohta, Megumi Narumi, Hirotsugu Sakaki, Manabu Seino, Takeshi Sudo, Satoru Nagase
Tumor lysis syndrome (TLS) is an oncological life-threatening complication characterized by hyperuricemia, hyperphosphatemia, and hyperkalemia, which can lead to acute renal failure, cardiac arrhythmias, cardiac arrest and seizures. Although TLS is a rare complication in patients with non-hematological malignancy, the mortality rate of TLS in solid tumors is higher than that in hematological malignancies. Acute renal injury is the most common cause of mortality associated with TLS in solid tumors. We report a case of TLS following chemotherapy for a recurrent uterine serous carcinoma...
May 2018: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29808366/merkel-cell-carcinoma-and-cellular-cytotoxicity-sensitivity-to-cellular-lysis-and-screening-for-potential-target-antigens-suitable-for-antibody-dependent-cellular-cytotoxicity
#11
Jocelyn Ollier, Thibault Kervarrec, Mahtab Samimi, Houssem Benlalam, Pascal Aumont, Régine Vivien, Antoine Touzé, Nathalie Labarrière, Henri Vié, Béatrice Clémenceau
The recent success of checkpoint inhibitors in the treatment of Merkel cell carcinoma (MCC) confirms that MCC tumors can be immunogenic. However, no treatment directly targeting the tumor is available for use in combination with these checkpoint inhibitors to enhance their efficacity. This study was carried out to characterize MCC line sensitivity to cellular lysis and to identify cell surface antigens that could be used for direct targeting of this tumor. For five representative MCC lines, the absence or low expression of MICA, MICB, HLA-I, and ICAM-1 was associated with low level of recognition by NK cells and T lymphocytes...
May 28, 2018: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29808140/skeletal-muscle-lymphoma-presenting-with-chronic-compartment-syndrome-of-leg-after-trauma
#12
Jhong-You Li, Chung-Liang Li, Chun-Kuan Lu
Compartment syndrome may be acute or chronic based on the clinical course and etiology. Here, we report the first known case to be diagnosed with skeletal muscle-derived B-cell lymphoma presenting with chronic compartment syndrome after trauma. A 62-year-old woman sought medical attention due to a one-month history of painful left lower leg swelling and paresthesia of the medial side of the foot after falling over. The patient underwent fasciotomy and debridement under the preoperative diagnosis of fasciitis and myositis with associated compressive neuropathy...
2018: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/29805983/neuroblastoma-cell-lines-are-refractory-to-genotoxic-drug-mediated-induction-of-ligands-for-nk-cell-activating-receptors
#13
Irene Veneziani, Elisa Brandetti, Marzia Ognibene, Annalisa Pezzolo, Vito Pistoia, Loredana Cifaldi
Neuroblastoma (NB), the most common extracranial solid tumor of childhood, causes death in almost 15% of children affected by cancer. Treatment of neuroblastoma is based on the combination of chemotherapy with other therapeutic interventions such as surgery, radiotherapy, use of differentiating agents, and immunotherapy. In particular, adoptive NK cell transfer is a new immune-therapeutic approach whose efficacy may be boosted by several anticancer agents able to induce the expression of ligands for NK cell-activating receptors, thus rendering cancer cells more susceptible to NK cell-mediated lysis...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29801143/tumor-lysis-syndrome
#14
Arjun Gupta, Joseph A Moore
No abstract text is available yet for this article.
May 10, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29797583/anti-tumor-specific-t-cell-responses-induced-by-oncolytic-adenovirus-oncos-102-in-peritoneal-mesothelioma-mouse-model
#15
Lukasz Kuryk, Anne-Sophie W Møller, Mariangela Garofalo, Vincenzo Cerullo, Sari Pesonen, Ramon Alemany, Magnus Jaderberg
Oncolytic adenoviral immunotherapy activates the innate immune system with subsequent induction of adaptive tumor-specific immune responses to fight cancer. Hence, oncolytic viruses do not only eradicate cancer cells by direct lysis, but also generate antitumor immune response allowing for long-lasting cancer control and tumor reduction. Their therapeutic effect can be further enhanced by arming the oncolytic adenovirus with co-stimulatory transgenes and/or co-administration with other anti-tumor therapies...
May 24, 2018: Journal of Medical Virology
https://www.readbyqxmd.com/read/29785403/immunotherapy-for-hepatocellular-carcinoma-current-advances-and-future-expectations
#16
REVIEW
Yingjun Xie, Yien Xiang, Jiyao Sheng, Dan Zhang, Xiaoxiao Yao, Yongsheng Yang, Xuewen Zhang
Primary liver cancer is a common kind of digestive cancers with high malignancy, causing 745,500 deaths each year. Hepatocellular carcinoma is the major pathological type of primary liver cancer. Traditional treatment methods for patients with hepatocellular carcinoma have shown poor efficacy in killing residual cancer cells for a long time. In recent years, tumor immunotherapy has emerged as a promising method owing to its safety and efficacy with respect to delaying the progression of advanced tumors and protecting postoperative patients against tumor relapse and metastasis...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29774202/loss-of-the-cyclin-dependent-kinase-inhibitor-1-in-the-context-of-brachyury-mediated-phenotypic-plasticity-drives-tumor-resistance-to-immune-attack
#17
Duane H Hamilton, Kristen K McCampbell, Claudia Palena
The acquisition of mesenchymal features by carcinoma cells is now recognized as a driver of metastasis and tumor resistance to a range of anticancer therapeutics, including chemotherapy, radiation, and certain small-molecule targeted therapies. With the recent successful implementation of immunotherapies for the treatment of various types of cancer, there is growing interest in understanding whether an immunological approach could be effective at eradicating carcinoma cells bearing mesenchymal features. Recent studies, however, demonstrated that carcinoma cells that have acquired mesenchymal features may also exhibit decreased susceptibility to lysis mediated by immune effector cells, including antigen-specific CD8+ T cells, innate natural killer (NK), and lymphokine-activated killer (LAK) cells...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29773661/phase-i-study-of-oncolytic-vaccinia-virus-gl-onc1-in-patients-with-peritoneal-carcinomatosis
#18
Ulrich M Lauer, Martina Schell, Julia Beil, Susanne Berchtold, Ursula Koppenhöfer, Jörg Glatzle, Alfred Königsrainer, Robert Möhle, Dominik Nann, Falko Fend, Christina Pfannenberg, Michael Bitzer, Nisar P Malek
OBJECTIVE: Peritoneal carcinomatosis (PC) is common in advanced tumor stages or disease recurrence arising from gastrointestinal cancers, gynecologic malignancies, or primary peritoneal carcinoma. Since current therapies are mostly ineffective, new thera-peutic approaches are needed. Here, we report on a phase I study designed to assess safety, MTD, and anti-tumor activity of intra-peri-toneal (i.p.) administration of oncolytic vaccinia virus GL-ONC1 in advanced stage PC patients. DESIGN: GL-ONC1 was administered i...
May 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29755779/immune-checkpoint-inhibitors-in-gastrointestinal-malignancies
#19
REVIEW
Vishal Jindal
Gastrointestinal (GIT) tumors are extremely fatal and lethal tumors with limited therapeutic options. Antitumor immunity is new line of research in management of solid tumors. Immune check points are negative regulators of immune system and control the immune response. These checkpoints are exploited by cancer cells. Cancer cells causes early activation of checkpoints and suppress the immune response, and therefore have unchecked growth and metastasis of malignant cells. Immune checkpoint inhibitors (ICIs), downregulates these checkpoints and activate the proliferation of cytotoxic T cells which helps in lysis of tumor cells...
April 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29755464/oncolytic-viral-therapy-and-the-immune-system-a-double-edged-sword-against-cancer
#20
REVIEW
Giulia Marelli, Anwen Howells, Nicholas R Lemoine, Yaohe Wang
Oncolytic viral therapy is a new promising strategy against cancer. Oncolytic viruses (OVs) can replicate in cancer cells but not in normal cells, leading to lysis of the tumor mass. Beside this primary effect, OVs can also stimulate the immune system. Tumors are an immuno-suppressive environment in which the immune system is silenced in order to avoid the immune response against cancer cells. The delivery of OVs into the tumor wakes up the immune system so that it can facilitate a strong and durable response against the tumor itself...
2018: Frontiers in Immunology
keyword
keyword
94518
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"